Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 2/2011

01.02.2011 | Original Paper

Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells

verfasst von: Dimitrios J. Stravopodis, Panagiotis K. Karkoulis, Eumorphia G. Konstantakou, Sophia Melachroinou, Angeliki Thanasopoulou, Gerasimos Aravantinos, Lukas H. Margaritis, Ema Anastasiadou, Gerassimos E. Voutsinas

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In search for more effective clinical protocols, the antimetabolite drug 5-fluorouracil (5-FU) has been successfully included in new regimens of bladder cancer combination chemotherapy. In the present study, we have investigated the effects of 5-FU treatment on apoptosis induction in wild-type and mutant p53 urinary bladder cancer cells.

Methods

We have used MTT-based assays, FACS analysis, Western blotting and semi-quantitative RT-PCR in RT4 and RT112 (grade I, wild-type p53), as well as in T24 (grade III, mutant p53) and TCCSUP (grade IV, mutant p53) human urinary bladder cancer cell lines.

Results

In the urothelial bladder cancer cell lines RT4 and T24, 5-FU-induced TS inhibition proved to be associated with cell type-dependent (a) sensitivity to the drug, (b) Caspase-mediated apoptosis, (c) p53 stabilization and activation, as well as Rb phosphorylation and E2F1 expression and (d) transcriptional regulation of p53 target genes and their cognate proteins, while an E2F-dependent transcriptional network did not seem to be critically engaged in such type of responses.

Conclusions

We have shown that in the wild-type p53 context of RT4 cells, 5-FU-triggered apoptosis was prominently efficient and mainly regulated by p53-dependent mechanisms, whereas the mutant p53 environment of T24 cells was able to provide notable levels of resistance to apoptosis, basically ascribed to E2F-independent, and still unidentified, pathways. Nevertheless, the differential vulnerability of RT4 and T24 cells to 5-FU administration could also be associated with cell-type-specific transcriptional expression patterns of certain genes critically involved in 5-FU metabolism.
Literatur
Zurück zum Zitat Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed Adamsen BL, Kravik KL, Clausen OP, De Angelis PM (2007) Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment. Int J Oncol 31:1491–1500PubMed
Zurück zum Zitat Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158PubMed Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 58:1149–1158PubMed
Zurück zum Zitat Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T, Fujii Y (2008) Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus 21:15–20PubMed Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Sugito N, Mori R, Ogawa R, Katada T, Fujii Y (2008) Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus 21:15–20PubMed
Zurück zum Zitat Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277:44376–44384CrossRefPubMed Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES (2002) Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 277:44376–44384CrossRefPubMed
Zurück zum Zitat Backes C, Kuentzer J, Lenhof HP, Comtesse N, Meese E (2005) GraBCas: a bioinformatics tool for score-based prediction of caspase- and granzyme B-cleavage sites in protein sequences. Nucleic Acids Res 33:W208–W213CrossRefPubMed Backes C, Kuentzer J, Lenhof HP, Comtesse N, Meese E (2005) GraBCas: a bioinformatics tool for score-based prediction of caspase- and granzyme B-cleavage sites in protein sequences. Nucleic Acids Res 33:W208–W213CrossRefPubMed
Zurück zum Zitat Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Pinedo HM, Peters GJ (2003) Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 39:1310–1317CrossRefPubMed Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Pinedo HM, Peters GJ (2003) Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 39:1310–1317CrossRefPubMed
Zurück zum Zitat Berger SH, Pittman DL, Wyatt MD (2008) Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol 76:697–706CrossRefPubMed Berger SH, Pittman DL, Wyatt MD (2008) Uracil in DNA: consequences for carcinogenesis and chemotherapy. Biochem Pharmacol 76:697–706CrossRefPubMed
Zurück zum Zitat Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitao C, Steer CJ, Rodrigues CM (2007) Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta 1772:40–47PubMed Borralho PM, Moreira da Silva IB, Aranha MM, Albuquerque C, Nobre Leitao C, Steer CJ, Rodrigues CM (2007) Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta 1772:40–47PubMed
Zurück zum Zitat Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG (2004) Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10:2158–2167CrossRefPubMed Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG (2004) Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin Cancer Res 10:2158–2167CrossRefPubMed
Zurück zum Zitat Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269CrossRefPubMed Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269CrossRefPubMed
Zurück zum Zitat Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staccioli MP, Baldelli AM, Brenna A, Valenti A, Muretto P, Catalano G (2000) Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 11:1053–1056CrossRefPubMed Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staccioli MP, Baldelli AM, Brenna A, Valenti A, Muretto P, Catalano G (2000) Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. Ann Oncol 11:1053–1056CrossRefPubMed
Zurück zum Zitat Dong S, Lester L, Johnson LF (2000) Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter. J Cell Biochem 77:50–64CrossRefPubMed Dong S, Lester L, Johnson LF (2000) Transcriptional control elements and complex initiation pattern of the TATA-less bidirectional human thymidylate synthase promoter. J Cell Biochem 77:50–64CrossRefPubMed
Zurück zum Zitat Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M (2008) Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 22:709–716PubMed Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD, Fukushima M (2008) Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 22:709–716PubMed
Zurück zum Zitat Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O’Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE (2004) Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 22:1572–1582CrossRefPubMed Garrity MM, Burgart LJ, Mahoney MR, Windschitl HE, Salim M, Wiesenfeld M, Krook JE, Michalak JC, Goldberg RM, O’Connell MJ, Furth AF, Sargent DJ, Murphy LM, Hill E, Riehle DL, Meyers CH, Witzig TE (2004) Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes’ B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 22:1572–1582CrossRefPubMed
Zurück zum Zitat Hegde SR, Sun W, Lynch JP (2008) Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2:135–149CrossRefPubMed Hegde SR, Sun W, Lynch JP (2008) Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol 2:135–149CrossRefPubMed
Zurück zum Zitat Iaquinta PJ, Lees JA (2007) Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19:649–657CrossRefPubMed Iaquinta PJ, Lees JA (2007) Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 19:649–657CrossRefPubMed
Zurück zum Zitat Ishibiki Y, Kitajima M, Sakamoto K, Tomiki Y, Sakamoto S, Kamano T (2003) Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer. J Int Med Res 31:181–187PubMed Ishibiki Y, Kitajima M, Sakamoto K, Tomiki Y, Sakamoto S, Kamano T (2003) Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer. J Int Med Res 31:181–187PubMed
Zurück zum Zitat Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412PubMed Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412PubMed
Zurück zum Zitat Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ (2009) Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 35:401–416PubMed Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ (2009) Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 35:401–416PubMed
Zurück zum Zitat Kubota Y, Miura T, Moriyama M, Noguchi S, Matsuzaki J, Takebayashi S, Hosaka M (1997) Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin Cancer Res 3:973–976PubMed Kubota Y, Miura T, Moriyama M, Noguchi S, Matsuzaki J, Takebayashi S, Hosaka M (1997) Thymidine phosphorylase activity in human bladder cancer: difference between superficial and invasive cancer. Clin Cancer Res 3:973–976PubMed
Zurück zum Zitat Le Francois BG, Maroun JA, Birnboim HC (2007) Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F. Br J Cancer 97:1242–1250CrossRefPubMed Le Francois BG, Maroun JA, Birnboim HC (2007) Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F. Br J Cancer 97:1242–1250CrossRefPubMed
Zurück zum Zitat Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250PubMed Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4:1243–1250PubMed
Zurück zum Zitat Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS (2006) Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer 106:1269–1275CrossRefPubMed Lin CC, Hsu CH, Huang CY, Cheng AL, Chen J, Vogelzang NJ, Pu YS (2006) Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity. Cancer 106:1269–1275CrossRefPubMed
Zurück zum Zitat Liu HC, Chen GG, Vlantis AC, Leung BC, Tong MC, van Hasselt CA (2006) 5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J 12:482–493CrossRefPubMed Liu HC, Chen GG, Vlantis AC, Leung BC, Tong MC, van Hasselt CA (2006) 5-fluorouracil mediates apoptosis and G1/S arrest in laryngeal squamous cell carcinoma via a p53-independent pathway. Cancer J 12:482–493CrossRefPubMed
Zurück zum Zitat Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338CrossRefPubMed Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338CrossRefPubMed
Zurück zum Zitat Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2’-deoxyuridine. World J Gastroenterol 10:172–176PubMed Ma T, Zhu ZG, Ji YB, Zhang Y, Yu YY, Liu BY, Yin HR, Lin YZ (2004) Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2’-deoxyuridine. World J Gastroenterol 10:172–176PubMed
Zurück zum Zitat Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S (2004) p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel. Oncol Rep 12:357–361PubMed Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S (2004) p53 dependence and apoptosis in response to FP treatment with p53-transfected colon cancer cell lines by use of thin layer collagen gel. Oncol Rep 12:357–361PubMed
Zurück zum Zitat Matsumoto M, Furihata M, Ohtsuki Y (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 39:79–87CrossRefPubMed Matsumoto M, Furihata M, Ohtsuki Y (2006) Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol 39:79–87CrossRefPubMed
Zurück zum Zitat Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193–5201PubMed Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61:5193–5201PubMed
Zurück zum Zitat Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T (2001) Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92:510–518CrossRefPubMed Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T (2001) Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92:510–518CrossRefPubMed
Zurück zum Zitat Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T (2004) Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100:723–731CrossRefPubMed Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T (2004) Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma. Cancer 100:723–731CrossRefPubMed
Zurück zum Zitat Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T (2008) Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61:587–594CrossRefPubMed Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y, Kurumi Y, Tani T (2008) Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61:587–594CrossRefPubMed
Zurück zum Zitat Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS (2004) Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214:19–33CrossRefPubMed Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS, Kim NS (2004) Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214:19–33CrossRefPubMed
Zurück zum Zitat Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194–205PubMed Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J, Calvert AH, Marsh S, McLeod HL, Bloemena E, Meijer S, Jansen G, van Groeningen CJ, Pinedo HM (2002) Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 1587:194–205PubMed
Zurück zum Zitat Poon RY, Jiang W, Toyoshima H, Hunter T (1996) Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271:13283–13291CrossRefPubMed Poon RY, Jiang W, Toyoshima H, Hunter T (1996) Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem 271:13283–13291CrossRefPubMed
Zurück zum Zitat Putzer BM (2007) E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 11:239–251CrossRefPubMed Putzer BM (2007) E2F1 death pathways as targets for cancer therapy. J Cell Mol Med 11:239–251CrossRefPubMed
Zurück zum Zitat Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL (2006) Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett 580:5905–5909CrossRefPubMed Real PJ, Sanz C, Gutierrez O, Pipaon C, Zubiaga AM, Fernandez-Luna JL (2006) Transcriptional activation of the proapoptotic bik gene by E2F proteins in cancer cells. FEBS Lett 580:5905–5909CrossRefPubMed
Zurück zum Zitat Reed MF, Zagorski WA, Knudsen ES (2007) RB activity alters checkpoint response and chemosensitivity in lung cancer lines. J Surg Res 142:364–372CrossRefPubMed Reed MF, Zagorski WA, Knudsen ES (2007) RB activity alters checkpoint response and chemosensitivity in lung cancer lines. J Surg Res 142:364–372CrossRefPubMed
Zurück zum Zitat Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402–412CrossRefPubMed Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9:402–412CrossRefPubMed
Zurück zum Zitat Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440–450CrossRefPubMed Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12:440–450CrossRefPubMed
Zurück zum Zitat Rustum YM (2004) Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9:2467–2473CrossRefPubMed Rustum YM (2004) Thymidylate synthase: a critical target in cancer therapy? Front Biosci 9:2467–2473CrossRefPubMed
Zurück zum Zitat Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327PubMed Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB, Danenberg PV (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322–1327PubMed
Zurück zum Zitat Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B (2008) Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19:915–919CrossRefPubMed Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B (2008) Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 19:915–919CrossRefPubMed
Zurück zum Zitat Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2:535–541PubMed Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R (2003) mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther 2:535–541PubMed
Zurück zum Zitat Stevens C, La Thangue NB (2004) The emerging role of E2F–1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 3:1071–1079CrossRef Stevens C, La Thangue NB (2004) The emerging role of E2F–1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 3:1071–1079CrossRef
Zurück zum Zitat Stravopodis DJ, Margaritis LH, Voutsinas GE (2007) Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 14:3122–3138CrossRefPubMed Stravopodis DJ, Margaritis LH, Voutsinas GE (2007) Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 14:3122–3138CrossRefPubMed
Zurück zum Zitat Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G, Margaritis LH, Voutsinas GE (2009) Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol 34:137–160PubMed Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G, Margaritis LH, Voutsinas GE (2009) Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol 34:137–160PubMed
Zurück zum Zitat Tozser J, Bagossi P, Zahuczky G, Specht SI, Majerova E, Copeland TD (2003) Effect of caspase cleavage-site phosphorylation on proteolysis. Biochem J 372:137–143CrossRefPubMed Tozser J, Bagossi P, Zahuczky G, Specht SI, Majerova E, Copeland TD (2003) Effect of caspase cleavage-site phosphorylation on proteolysis. Biochem J 372:137–143CrossRefPubMed
Zurück zum Zitat Van Triest B, Pinedo HM, Giaccone G, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385–391CrossRefPubMed Van Triest B, Pinedo HM, Giaccone G, Peters GJ (2000) Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann Oncol 11:385–391CrossRefPubMed
Zurück zum Zitat Vousden KH (2002) Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602:47–59PubMed Vousden KH (2002) Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 1602:47–59PubMed
Zurück zum Zitat Wang W, McLeod HL, Cassidy J (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104:504–511CrossRefPubMed Wang W, McLeod HL, Cassidy J (2003) Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer 104:504–511CrossRefPubMed
Zurück zum Zitat Wang W, McLeod HL, Cassidy J, Collie-Duguid ES (2007) Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 59:839–845CrossRefPubMed Wang W, McLeod HL, Cassidy J, Collie-Duguid ES (2007) Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks. Cancer Chemother Pharmacol 59:839–845CrossRefPubMed
Zurück zum Zitat Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207–219CrossRefPubMed Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu Y, Weng Z, Liu J, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu ET, Yu Q, Ng HH, Ruan Y (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207–219CrossRefPubMed
Zurück zum Zitat Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rodel C (2007) Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072–1080CrossRefPubMed Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, Rodel C (2007) Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 68:1072–1080CrossRefPubMed
Zurück zum Zitat Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23:5635–5643CrossRefPubMed Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23:5635–5643CrossRefPubMed
Zurück zum Zitat Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772CrossRefPubMed Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761–772CrossRefPubMed
Zurück zum Zitat Wyatt MD, Wilson DM 3rd (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66:788–799CrossRefPubMed Wyatt MD, Wilson DM 3rd (2009) Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 66:788–799CrossRefPubMed
Zurück zum Zitat Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1999) Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46:610–615PubMed Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1999) Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology 46:610–615PubMed
Metadaten
Titel
Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells
verfasst von
Dimitrios J. Stravopodis
Panagiotis K. Karkoulis
Eumorphia G. Konstantakou
Sophia Melachroinou
Angeliki Thanasopoulou
Gerasimos Aravantinos
Lukas H. Margaritis
Ema Anastasiadou
Gerassimos E. Voutsinas
Publikationsdatum
01.02.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 2/2011
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-010-0891-y

Weitere Artikel der Ausgabe 2/2011

Journal of Cancer Research and Clinical Oncology 2/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.